Do immune cells promote the pathology of dystrophin-deficient myopathies?
about
Expression profiling of cytokines and related genes in regenerating skeletal muscle after cardiotoxin injection: a role for osteopontinNutraceuticals and Their Potential to Treat Duchenne Muscular Dystrophy: Separating the Credible from the ConjectureThe role of oxidative stress in skeletal muscle injury and regeneration: focus on antioxidant enzymesUse of cell permeable NBD peptides for suppression of inflammationThree-dimensional optical coherence micro-elastography of skeletal muscle tissue.SMAD signaling drives heart and muscle dysfunction in a Drosophila model of muscular dystrophyPotent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chain-deficient muscular dystrophy.Use of imaging biomarkers to assess perfusion and glucose metabolism in the skeletal muscle of dystrophic mice.Therapeutic targeting of signaling pathways in muscular dystrophy.Markers of degeneration and regeneration in Duchenne muscular dystrophyA mathematical model of skeletal muscle disease and immune response in the mdx mouse.Alignment of gene expression profiles from test samples against a reference database: New method for context-specific interpretation of microarray data.Green tea extract decreases muscle pathology and NF-kappaB immunostaining in regenerating muscle fibers of mdx mice.Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice.Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans.Effects of irradiating adult mdx mice before full-length dystrophin cDNA transfer on host anti-dystrophin immunityCarbamylated erythropoietin does not alleviate signs of dystrophy in mdx mice.Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1AAge-related impairment of T cell-induced skeletal muscle precursor cell function.A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy.Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans.Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophyRapamycin ameliorates dystrophic phenotype in mdx mouse skeletal muscle.IL-6 Blockade as a Therapeutic Approach for Duchenne Muscular Dystrophy.Pentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trial.The immune system in Duchenne muscular dystrophy: Friend or foe.uPA deficiency exacerbates muscular dystrophy in MDX mice.Deletion of Galgt2 (B4Galnt2) reduces muscle growth in response to acute injury and increases muscle inflammation and pathology in dystrophin-deficient miceAdeno-associated virus serotype 8 (AAV8) delivery of recombinant A20 to skeletal muscle reduces pathological activation of nuclear factor (NF)-κB in muscle of mdx mice.Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy.Nanolipodendrosome-loaded glatiramer acetate and myogenic differentiation 1 as augmentation therapeutic strategy approaches in muscular dystrophyWasting mechanisms in muscular dystrophy.Skeletal muscle diseases, inflammation, and NF-kappaB signaling: insights and opportunities for therapeutic intervention.Protein-DNA array-based identification of transcription factor activities differentially regulated in skeletal muscle of normal and dystrophin-deficient mdx mice.Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention.Distinct roles of TRAF6 at early and late stages of muscle pathology in the mdx model of Duchenne muscular dystrophy.Exacerbation of pathology by oxidative stress in respiratory and locomotor muscles with Duchenne muscular dystrophy.Contribution of oxidative stress to pathology in diaphragm and limb muscles with Duchenne muscular dystrophy.Effects of T-lymphocyte depletion on muscle fibrosis in the mdx mouse.Co-administration of deflazacort and doxycycline: a potential pharmacotherapy for Duchenne muscular dystrophy.
P2860
Q24685614-C3CA08BA-549D-4712-B1CD-D9FAB23824AAQ28072269-502A974E-F6F1-48C3-B856-852911F3EF7AQ28076877-4CEFDBD3-A376-4088-A44B-E02CB0CA4CC6Q28268290-103149C5-C4EA-4FFB-AEA2-8F9431022647Q30426112-DEB3BF09-F206-46C9-8045-278FF95D108CQ30498086-F48A2D77-053B-47E2-89AE-2EB8BE8705B5Q30841381-3BC35C8A-B131-4367-A06B-4C2F1F185631Q31015982-827A7EA2-434F-4AE9-8D6B-9770BB52BB32Q33707964-91F61F6F-D204-4BE1-AF48-EEA6F797054FQ33807694-10D75744-C36E-4C54-8BFB-74574F53CAD6Q33810272-BE90B0F9-F123-4998-9764-96885DC37DB2Q33859024-BEAF4B5E-55B8-4E65-B528-2DAC74D000AAQ33901041-FC1EF2B5-103B-4703-ACF0-A2C16341AAAFQ33947243-DB5AB79E-1BAA-4A73-BD9A-EB49C34C6D9AQ34124872-1D6EA40E-CB71-4C03-9580-C16D3C65BECAQ34632501-182C26BC-D6B6-4FD8-800F-16F4EC1CD069Q34674989-9B45AA13-42EB-44DB-908E-5806AD28637FQ34994784-87B5DA97-B159-4EB9-A364-E21D125A1362Q35055585-FFD5FCC9-84AB-4B37-8E38-13FD66FE57AEQ35100498-7E51CE46-7B70-4F98-AE9A-01C029083931Q35148782-6D91247B-F2D2-436F-9175-833A9AE51D5AQ35175749-A908D390-8945-4C8B-848E-AE48D70FFD06Q35286959-A6187B5E-06E4-4C08-BC5A-D703E6118A3FQ35800719-41B53C79-2A1B-4CBE-91DA-E1110322B3F8Q35835703-25F9FFD8-47C7-4B00-A507-7FFF96AB07E2Q36105761-D33DB69A-7934-4441-BCDD-B631C978861AQ36119288-DDF1B65F-B5E6-4E0E-8202-D59BFB2C4E33Q36167600-8682B483-CD99-49B6-97B6-7E5BBFC08420Q36621772-8F55BA21-7331-47C7-B973-EF31DDDCD816Q36957496-A59FB165-9106-4EEC-B9DF-7636368895DAQ37095736-6034174C-8625-4676-9A8F-4D26829EECEFQ37138490-358449AA-7CF6-46D5-8B7D-E7EF0C4D340FQ37293352-CED72F96-9E73-48F1-9200-0A398EF92C68Q37447128-5E6A3586-7040-4601-AEBF-85521DB6D445Q37583167-51BB3D22-ECFD-45D1-B4A0-925101A6F5A5Q37593034-18C2BBB1-BE11-409A-B8D5-C5628A454A68Q37864433-BD9F5CF6-D386-4C43-8C67-208B22D4408FQ38056065-CA295FF5-067B-4F10-8787-3996C176440DQ38586130-C120DDB3-C61C-422A-8525-1E7B3E4B6D6DQ40955126-9B795D5D-C9CD-43E5-A027-8043A5974337
P2860
Do immune cells promote the pathology of dystrophin-deficient myopathies?
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Do immune cells promote the pathology of dystrophin-deficient myopathies?
@ast
Do immune cells promote the pathology of dystrophin-deficient myopathies?
@en
Do immune cells promote the pathology of dystrophin-deficient myopathies?
@nl
type
label
Do immune cells promote the pathology of dystrophin-deficient myopathies?
@ast
Do immune cells promote the pathology of dystrophin-deficient myopathies?
@en
Do immune cells promote the pathology of dystrophin-deficient myopathies?
@nl
prefLabel
Do immune cells promote the pathology of dystrophin-deficient myopathies?
@ast
Do immune cells promote the pathology of dystrophin-deficient myopathies?
@en
Do immune cells promote the pathology of dystrophin-deficient myopathies?
@nl
P1476
Do immune cells promote the pathology of dystrophin-deficient myopathies?
@en
P2093
Spencer MJ
Tidball JG
P304
P356
10.1016/S0960-8966(01)00198-5
P577
2001-09-01T00:00:00Z